Jove
Visualize
Contact Us

Related Experiment Videos

New molecular markers in resistant B-CLL.

Julien Bouley1, Ludovic Deriano, Jozo Delic

  • 1Laboratoire de Radiobiologie et Oncologie, CEA, DSV-DRR, Fontenay aux Roses, France.

Leukemia & Lymphoma
|June 7, 2006
PubMed
Summary

Predicting B-chronic lymphocytic leukemia (B-CLL) course is challenging due to molecular variations. New markers, including genome stability factors and B-cell receptor signaling proteins, aid in predicting treatment response and understanding disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymerase theta repairs persistent G1-induced DNA breaks in S-phase during class switch recombination.

Nature communications·2025
Same author

Senataxin promotes recombination fidelity during antigen receptor gene diversification.

Science signaling·2025
Same author

CST Is Epistatic With Shieldin to Limit DNA Double-Strand Break End Resection and Promote Repair During Igh Class Switch Recombination.

European journal of immunology·2025
Same author

CD38/NAD<sup>+</sup> glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies.

Biochimie·2024
Same author

ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.

Leukemia·2023
Same author

Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia.

Cell stem cell·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • B-chronic lymphocytic leukemia (B-CLL) exhibits significant clinical course variability.
  • This variability is linked to complex molecular alterations within malignant cells.
  • Identifying predictive molecular markers is crucial for tailored B-CLL treatments.

Purpose of the Study:

  • To review and discuss novel molecular markers for predicting B-CLL clinical course and treatment response.
  • To explore the association between these markers and B-cell receptor signaling pathways.
  • To highlight the potential of these markers in understanding multi-drug resistance in B-CLL.

Main Methods:

  • Review of recent studies focusing on molecular markers in B-CLL.
  • Analysis of established markers like immunoglobulin heavy chain variable (IgVH) gene mutation status.

Related Experiment Videos

  • Inclusion of novel markers: genome stability factors (telomere function, DNA repair, ATM, p53) and B-cell receptor signaling components (Zap-70).

    • Main Results:

    • IgVH mutation status is a well-established predictive factor.
    • Defects in genome stability and B-cell receptor signaling factors correlate with B-CLL variability.
    • Absence of somatic IgVH mutations may relate to epigenetic events or inherited immune defects.
    • Zap-70 expression/phosphorylation may indicate defective pathways rather than malignancy.
    • Specific marker subsets are associated with treatment resistance.

    Conclusions:

    • Novel molecular markers offer improved prediction of B-CLL clinical course and treatment outcomes.
    • Understanding these markers aids in deciphering disease mechanisms, including multi-drug resistance.
    • Gene expression profiling and proteomic analyses are expected to further elucidate affected pathways in B-CLL.